The global Biotechnology Market was valued at USD 761.5 Billion in 2024 and is projected to reach USD 1,315.9 Billion by 2033, demonstrating a CAGR of 6.27% during the forecast period of 2025–2033. Growth is driven by advancements in genetic engineering, increasing R&D in personalized medicine, and rising demand for sustainable agriculture. 

Study Assumption Years

• Base Year: 2024
• Historical Year/Period: 2019-2024
• Forecast Year/Period: 2025-2033

Biotechnology Market Key Takeaways

• Current Market Size: USD 761.5 Billion in 2024
• CAGR: 6.27% during 2025-2033
• Forecast Period: 2025-2033
• The biotechnology sector encompasses genetic engineering, biopharmaceuticals, bioinformatics, and synthetic biology impacting healthcare, agriculture, and environmental management.
• Innovation in gene editing and personalized medicine, supported by high genetic research growth, is a primary market driver.
• The rising incidence of chronic diseases and demand for targeted biopharmaceuticals boosts market growth.
• Sustainable agriculture needs, including development of GM crops and biopesticides, further propel adoption of biotechnological methods.
• Bioinformatics and the integration of IT in biotechnology enhance R&D capabilities, driving market expansion.

Sample Request Link: 

https://www.imarcgroup.com/biotechnology-market/requestsample

Market Growth Factors

The biotechnology market growth is chiefly propelled by increasing innovations in gene editing, personalized medicine, and treatments, fueled by extensive genetic research and molecular biology advancements. High incidence of chronic diseases necessitates drug-specific treatments, raising demand for biopharmaceuticals and precision medicine, which strongly contributes to market expansion. Moreover, the global push for sustainable farming due to population growth and limited arable land has accelerated the adoption of biotech in crop improvements and biopesticides. These combined factors underpin the sustained market growth through 2033.

Rapid advancements in genetic engineering, notably CRISPR-Cas9 technology, enable scientists to modify genes precisely. This has wide applications in medicine, agriculture, and industrial manufacturing. In healthcare, engineered gene therapies target genetic disorders and cancers, facilitating personalized treatments and transforming pharmaceutical manufacturing via engineered microbes that produce vital compounds like insulin. This revolution in genetic engineering fosters innovation, enhances therapeutic efficacy, and diversifies biotech product offerings, driving the market upward.

The rising demand for sustainable agricultural solutions underlines the market growth. Driven by food demand increases and environmental considerations, biotechnology supports development of genetically modified crops with improved yield, pest resistance, and enhanced nutrition. Eco-friendly biopesticides are replacing traditional chemicals, reducing environmental impact. Additionally, biotechnology optimizes plant traits for better climate resilience and nutrient efficiency, contributing to food security and sustainable resources. This agricultural biotech adoption responds to critical global challenges, promoting the biotechnology market’s positive trajectory.

Market Segmentation

By Product Type:

• Instruments: Core tools enabling precise research, diagnostics, and experimentation.
• Reagents: Essential substances fueling experiments, facilitating accurate results.
• Software and Services: Includes software for data analysis, visualization, integration, and support services like consulting and training, enhancing biotech efficiency.

By Technology:

• Nanobiotechnology: Combines nanoscale materials with biological systems to revolutionize drug delivery and diagnostics.
• Tissue Engineering and Regeneration: Develops functional tissues to address organ shortages and medical needs.
• DNA Sequencing: Enables comprehensive genomic analysis for personalized medicine and disease insight.
• Cell-Based Assays: Offers understanding of cellular behavior aiding drug development and toxicity evaluation.
• Fermentation: Foundation for bioprocessing, producing biofuels, pharmaceuticals, and enzymes.
• PCR Technology: Amplifies DNA for diagnostics and genetic research.
• Chromatography: Separates biomolecules precisely, critical in drug purification and analytics.
• Others: Includes additional emerging biotechnologies.

By Application:

• Healthcare: Largest segment; biotechnology plays a critical role in diagnostics, treatment, and personalized medicine innovations.
• Food and Agriculture: Biotechnology improves crop yield, pest resistance, and nutritional content.
• Natural Resources and Environment: Biotech contributes to sustainable resource management and environmental protection.
• Industrial Processing: Utilizes biotechnology for efficient manufacturing and processing.
• Bioinformatics: Integrates IT and biological data for research and development optimizations.
• Others: Additional applications across diverse sectors.

By Region:

• Asia Pacific
• Europe
• North America
• Latin America
• Middle East and Africa

Regional Insights

North America dominates the biotechnology market due to its robust ecosystem of research, innovation, and strong industry collaboration. The region benefits from substantial investment in R&D, established regulatory frameworks, and concentration of leading universities and biotech firms. Entrepreneurial and venture capital emphasis further accelerates commercialization of innovative biotech solutions. North America's historical leadership in genomics, pharmaceuticals, and medical devices drives global biotech growth and innovation.

Recent Developments & News

• May 2025: Biogen and City Therapeutics partnered to develop RNA interference (RNAi) therapies for central nervous system diseases, combining City Therapeutics’ RNAi platform with Biogen’s delivery technology.
• May 2025: Biocon Biologics, via partner Yoshindo Inc., launched Ustekinumab BS Subcutaneous Injection [YD] in Japan, a biosimilar targeting psoriasis and psoriatic arthritis.
• April 2025: Novartis announced a USD 23 Billion investment over five years to enhance its US biotech footprint, adding facilities and thousands of jobs focused on biologics and radioligand therapy.
• April 2025: Amgen invested USD 900 Million to expand its Ohio biologics manufacturing site, increasing total investment to over USD 1.4 Billion and job count to 750.
• March 2025: Roche opened the Roche Genentech Innovation Center Boston at Harvard’s Enterprise Research Campus, focusing on cardiovascular, renal, and metabolism diseases, employing up to 500 people.

Key Players

• Amgen Inc.
• Biocon Limited
• Biogen Inc.
• F. Hoffmann-La Roche AG
• Genmab A/S
• Lonza Group AG
• Novartis AG
• Novo Nordisk A/S
• Pfizer Inc.
• Regeneron Pharmaceuticals Inc.
• Seagen Inc.
• Syngenta AG
• Vertex Pharmaceuticals Incorporated

Get Custom Market Research Report for Your Business:

https://www.imarcgroup.com/request?type=report&id=5785&flag=E

If you require any specific information that is not covered currently within the scope of the report, we will provide the same as a part of the customization.

About Us

IMARC Group is a global management consulting firm that helps the world’s most ambitious changemakers to create a lasting impact. The company provide a comprehensive suite of market entry and expansion services. IMARC offerings include thorough market assessment, feasibility studies, company incorporation assistance, factory setup support, regulatory approvals and licensing navigation, branding, marketing and sales strategies, competitive landscape and benchmarking analyses, pricing and cost research, and procurement research.

Contact Us

IMARC Group,

134 N 4th St. Brooklyn, NY 11249, USA,

Email: sales@imarcgroup.com,

Tel No: (D) +91 120 433 0800,

United States: +1-201971-6302